1/10
09:26 pm
xers
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? [Yahoo! Finance]
1/10
02:58 pm
xers
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns [Yahoo! Finance]
Low
Report
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns [Yahoo! Finance]
1/10
04:43 am
xers
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents [Yahoo! Finance]
Low
Report
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents [Yahoo! Finance]
1/9
08:38 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
1/8
07:27 am
xers
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue [Yahoo! Finance]
Medium
Report
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue [Yahoo! Finance]
1/8
07:00 am
xers
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
High
Report
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
1/2
04:15 pm
xers
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/2
12:50 am
xers
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday [Yahoo! Finance]
Medium
Report
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday [Yahoo! Finance]
1/1
10:55 pm
xers
US FDA declines to approve Corcept's drug for rare hormonal disorder [Yahoo! Finance]
Medium
Report
US FDA declines to approve Corcept's drug for rare hormonal disorder [Yahoo! Finance]
12/18
01:07 am
xers
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) [Seeking Alpha]
Low
Report
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) [Seeking Alpha]
12/10
07:18 am
xers
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
12/8
05:04 pm
xers
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
12/6
04:23 am
xers
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? [Yahoo! Finance]
Medium
Report
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? [Yahoo! Finance]
12/3
11:43 am
xers
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]
Low
Report
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]
12/1
07:00 am
xers
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
Medium
Report
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
11/12
08:11 am
xers
Xeris Biopharma (NASDAQ:XERS) had its price target raised by analysts at Piper Sandler from $6.00 to $8.00. They now have a "neutral" rating on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its price target raised by analysts at Piper Sandler from $6.00 to $8.00. They now have a "neutral" rating on the stock.
11/12
08:11 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/12
08:11 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
11/9
07:03 pm
xers
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
Low
Report
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
11/6
09:50 am
xers
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript [Yahoo! Finance]
Low
Report
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript [Yahoo! Finance]
11/6
07:43 am
xers
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 [Yahoo! Finance]
Low
Report
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 [Yahoo! Finance]
11/6
07:00 am
xers
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
High
Report
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
11/1
06:55 am
xers
Xeris Biopharma (NASDAQ:XERS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Xeris Biopharma (NASDAQ:XERS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
10/29
10:07 am
xers
Xeris Biopharma (NASDAQ:XERS) was given a new $18.00 price target on by analysts at Oppenheimer Holdings, Inc..
Low
Report
Xeris Biopharma (NASDAQ:XERS) was given a new $18.00 price target on by analysts at Oppenheimer Holdings, Inc..
10/24
12:26 pm
xers
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.